Alyeska Investment Group
NDRM

Alyeska Investment Group’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Alyeska Investment Group’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-52,041
Closed -$698K – 650
2015
Q1 		$698K Buy
52,041
+3,826
+8% +$47.1K 0.01% 455
2014
Q4 		$677K Buy
+48,215
New +$381K 0.01% 422

Other funds holding NDRM

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Alyeska Investment Group's NDRM Position: Q2 2015 in Review

Alyeska Investment Group sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q2 2015, closing a stake of 52,041 shares — an estimated $698K sold.

Alyeska Investment Group first reported a position in NDRM in Q4 2014 and held it in 2 quarters. The position peaked at $698K in Q1 2015. 21 funds tracked by Wall St. Rank hold NDRM as of Q2 2015.

  • Alyeska Investment Group reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q2 2015 after selling out during the quarter.
  • Alyeska Investment Group sold 52,041 NeuroDerm Ltd. Ordinary Shares shares in Q2 2015, an estimated $698K.
  • Alyeska Investment Group first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2014 and held it in 2 quarters.
  • Alyeska Investment Group's NeuroDerm Ltd. Ordinary Shares position peaked at $698K in Q1 2015.
  • 21 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q2 2015.

Based on Alyeska Investment Group's 13F filing for Q2 2015, filed 14 Aug 2015.